Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
Authors:
- Zijun WangZWZijun Wang
- Frauke MueckschFMFrauke Muecksch
- Friederike MuennFMFriederike Muenn
- Alice ChoACAlice Cho
- Shuai ZongSZShuai Zong
- Raphael RaspeRRRaphael Raspe
- Victor RamosVRVictor Ramos
- Brianna JohnsonBJBrianna Johnson
- Tarek Ben TanfousTTTarek Ben Tanfous
- Justin DaSilvaJDJustin DaSilva
- Eva BednarskiEBEva Bednarski
- Camila Guzman-CardozoCGCamila Guzman-Cardozo
Open Access
- 25 August 2022
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (10)
Abstract
The SARS-CoV-2 pandemic prompted a global vaccination effort and the development of numerous COVID-19 vaccines at an unprecedented scale and pace. As a result, current COVID-19 vaccination regimens comprise diverse vaccine modalities, immunogen combinations, and dosing intervals. Here, we compare vaccine-specific antibody and memory B cell responses following two-dose mRNA, single-dose Ad26.COV.2S, and two-dose ChAdOx1, or combination ChAdOx1/mRNA vaccination. Plasma-neutralizing activity, as well as the magnitude, clonal composition, and antibody maturation of the RBD-specific memory B cell compartments, showed substantial differences between the vaccination regimens. While individual monoclonal antibodies derived from memory B cells exhibited similar binding affinities and neutralizing potency against Wuhan-Hu-1 SARS-CoV-2, there were significant differences in epitope specificity and neutralizing breadth against viral variants of concern. Although the ChAdOx1 vaccine was inferior to mRNA and Ad26.COV.2S in several respects, biochemical and structural analyses revealed enrichment in a subgroup of memory B cell neutralizing antibodies with distinct RBD-binding properties resulting in remarkable potency and breadth.Keywords
All Related Versions
Funding Information
- National Center for Advancing Translational Sciences
- National Institutes of Health (P01-AI138398-S1, 2U19AI111825, R37-AI64003, R01AI78788, P01AI165075)
- Federal Institute for Drugs and Medical Devices (V-2021.3/1503_68403/2021–2022)
- Deutsche Forschungsgemeinschaft
- Charité Universitätsmedizin Berlin
- Bulgari Women and Science Fellowship
- National Institutes of Health Clinical and Translational Science (UL1 TR001866)
- Howard Hughes Medical Institute
- Shapiro-Silverberg Fund for the Advancement of Translational Research
This publication has 69 references indexed in Scilit:
- UCSF ChimeraX: Meeting modern challenges in visualization and analysisProtein Science, 2017
- cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determinationNature Methods, 2017
- A Public Database of Memory and Naive B-Cell Receptor SequencesPLOS ONE, 2016
- High resolution single particle refinement in EMAN2.1Methods, 2016
- Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing dataBioinformatics, 2015
- Fast, scalable generation of high‐quality protein multiple sequence alignments using Clustal OmegaMolecular Systems Biology, 2011
- Features and development of CootActa Crystallographica Section D Structural Biology, 2010
- Duration of Humoral Immunity to Common Viral and Vaccine AntigensNew England Journal of Medicine, 2007
- Automated electron microscope tomography using robust prediction of specimen movementsJournal of Structural Biology, 2005
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004